CN108066770A - Amphipathic nature polyalcohol prodrug of reduction response release active compound and preparation method thereof - Google Patents
Amphipathic nature polyalcohol prodrug of reduction response release active compound and preparation method thereof Download PDFInfo
- Publication number
- CN108066770A CN108066770A CN201611007592.5A CN201611007592A CN108066770A CN 108066770 A CN108066770 A CN 108066770A CN 201611007592 A CN201611007592 A CN 201611007592A CN 108066770 A CN108066770 A CN 108066770A
- Authority
- CN
- China
- Prior art keywords
- prodrug
- active compound
- release active
- amphipathic nature
- nature polyalcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
- C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
Abstract
The present invention relates to a kind of amphipathic nature polyalcohol prodrugs for reducing response release active compound and preparation method thereof, and the method for the present invention has many advantages, such as that applicable medicament categories are more, raw material is easy to get, yield and purity are high.Hydrophilic polymer and hydrophobic drug in amphipathic nature polyalcohol prodrug of the present invention are linked by containing the linking arm of type self-destroyed disulfide bond, in tumour cell reducing environment, molecular rearrangement occurs for disulfide bonds, release active compound molecule, ensure the activity of drug, and nano-micelle can be self-assembled into aqueous medium, be expected to realize long-acting cycling in vivo, it improves and is gathered in tumor tissues, so as to achieve the purpose that improve curative effect of medication and reduce toxic side effect.
Description
Technical field
The invention belongs to pharmaceutical chemistry technical fields, and in particular to one kind that hydrophilic polymer is formed with hydrophobic drug
Amphipathic prodrug of reduction response release active compound and preparation method thereof.
Background technology
Chemotherapy is a kind of basic tumor therapeuticing method, mainly kills tumour cell using anticancer drug and reaches treatment
The purpose of tumour.Clinically common anticancer drug mainly includes camptothecin, taxanes, vincaleukoblastinum and Anthraquinones etc., this
A little anticancer drug physicochemical properties are poor (such as being insoluble in water, poor selectivity etc.), there is serious poison pair to normal cell and tissue
Effect, causes chemotherapy of tumors effect poor, therefore clinical practice is restricted.
Hydrophilic radical is introduced by chemical modification, water-soluble prodrug is prepared, can effectively solve the water solubility of drug
Problem.In high molecular weight water soluble polymer, polyethylene glycol is got the attention.Polyethylene glycol is that a kind of biocompatibility is excellent
Different high molecular material, be approved by the FDA in the United States for can internal injection one of medicinal high molecular polymer.Drug is through poly- second
After glycol modification, water-soluble and internal stability is improved, and can significantly reduce kidney clearance rate, is greatly prolonged blood and is followed
The ring time, moreover it is possible to the accumulation at tumour be enhanced by EPR effects, these are to improving oncotherapy effect, reducing toxic side effect
It is of crucial importance.
In recent years, administration nano-drug administration system is had received widespread attention with its good characteristic, and administration nano-drug administration system has following
Feature:It largely improves the water solubility of drug, realized by improving permeability and reserve effects (EPR) to the passive of tumour
Targeting extends circulation time in vivo, improves utilization ratio of drug and reduces toxic side effect etc..However, common nanometer formulation is simultaneously
It cannot identify tumor locus and normal portions, intracellular and extracellular environment can not be distinguished, therefore how allow nanometer formulation
The selective active compound that releases is still a great problem in vivo.
The study found that intracellular glutathione concentrations (0.5~10mM/L) are extracellular glutathione concentrations (2~20 μ
M/L) 200 times or more, disulfide bond is in the presence of the reducing agents such as a certain amount of glutathione (GSH) or dithiothreitol (DTT) (DTT)
It is reduced generation sulfydryl, but highly stable, i.e., extracellular paddy Guang under the environment such as normal body temperature, p H and oxidation in human body
Sweet peptide concentration is not enough to Reduction of Disulfide, in addition, tumor tissue cell is than normal tissue cell anoxic, with more reproducibility ring
Border.Therefore, hydrophilic polymer and hydrophobic drug by disulfide bond can be linked, and is self-assembled into receives in a solvent
Rice glue beam is entered after target cell by endocytosis and is reduced by GSH, i.e. disulfide bonds generation sulfydryl, so as to quickly have
Effect ground release drug, and the structures such as nucleus are diffused into, so as to kill cancer cell.Current most common disulfide bond linking arm is main
For 3, with prodrug of 3, the 3 '-dithiodipropionic acid as linking arm, item is reduced in GSH, DTT etc. for 3 '-dithiodipropionic acid
Under part, disulfide bond is broken rapidly, but the drug discharged would generally be with " tail " rather than active compound molecular forms.
The content of the invention
An object of the present invention is to provide a kind of amphipathic nature polyalcohol prodrug for reducing response release active compound, reaches
Increase water-soluble, cancer target and reduce the effect of toxicity.
The second object of the present invention is to provide a kind of system for the amphipathic nature polyalcohol prodrug for reducing response release active compound
Preparation Method.
The third object of the present invention is to provide a kind of receiving for amphipathic nature polyalcohol prodrug for reducing response release active compound
Rice micellar preparation.
The fourth object of the present invention is to provide a kind of amphipathic nature polyalcohol prodrug for reducing response release active compound and is making
Application in standby antitumor drug.
The present invention technical solution be：
The amphipathic nature polyalcohol prodrug of reduction response release active compound provided by the invention, which is characterized in that poly- second two
It is combined between alcohols and hydrophobic drug by containing the linking arm of type self-destroyed disulfide bond, with below formula：
Wherein, n is 5~400；M is 1 or 2；R is hydrophobic anticancer drug.
R be hydroxyl building stone antitumor drug, including camptothecin (camptothecine, Irinotecan, topotecan,
10-hydroxycamptothecine, 7-Ethyl-10-hydroxycamptothecin etc.) or taxanes (taxol, Docetaxel, Cabazitaxel
Deng) or vinca (vincaleukoblastinum, vincristine, vinorelbine etc.) etc..
The amphipathic nature polyalcohol prodrug of reduction response release active compound provided by the invention, it is preferred that m 1 has
Below formula：
Wherein, the polyethylene glycol average molecular weight is in 500~20,000 dalton；Connecting key is small point containing disulfide bond
Sub- linking arm.
The preparation method of the amphipathic nature polyalcohol prodrug of present invention reduction response release active compound, includes the following steps：
(1) 4- bromo-butyric acids are reacted with thiocarbamide, obtain 4- mercaptobutyric acids；
4- (the 2- pyridyl groups two containing disulfide bond are obtained by the reaction in the 4- mercaptobutyric acids that two pyridine of (2) two sulphur is obtained with step (1)
Sulfenyl) butyric acid；
(3) 4- (2- pyridyidithios) butyric acid containing disulfide bond that step (2) obtains exists with hydrophobic anticancer drug
Under catalyst action, by being condensed to yield 4- (2- pyridyidithios) butyric acid drug conjugates；
(4) 4- (2- pyridyidithios) the butyric acid drug conjugates that step (3) obtains pass through with sulfydryl polyethylene glycol
Thiol disulfide exchange reaction, obtains the polyethylene glycol anticancer prodrugs containing disulfide bond, i.e. reduction response discharges active compound
Amphipathic nature polyalcohol prodrug.
Wherein, specifically, step (1) includes following reaction step：By 4- bromo-butyric acids and thiocarbamide in molar ratio 1:1~1:3
Add in ethyl alcohol in, reflux 2~8 it is small when, then add in NaOH ethanol solutions continue reflux 6~20 it is small when, cooling, filtering, dissolving,
Ether is washed, liquid separation, adjusts pH, extraction, dry 4- mercaptobutyric acids；
Step (2) includes following reaction step：By 4- mercaptobutyric acids and two sulphur, two pyridine in molar ratio 1:1~1:5 are dissolved in
In methanol, react at room temperature 1~5 it is small when, concentration, neutral alumina column and silica gel post separation, concentration, dry 4- (2- pyridines
Base disulfide group) butyric acid；
Step (3) includes following reaction step：In the presence of condensing agent and organic amine, by hydrophobic anticancer drug and 4-
(2- pyridyidithios) butyric acid in molar ratio 1:1~1:3 are dissolved in DMF, and when room temperature reaction 36~72 is small, reaction solution is through acid
It washes, neutralize, liquid separation, drying, silica gel column purification, concentration, being dried in vacuo to obtain 4- (2- pyridyidithios) butyric acid drug conjugates；
Step (4) includes following reaction step：Under nitrogen protection, sulfydryl polyethylene glycol is added dropwise under stirring condition
Into the DMF solution of 4- (2- pyridyidithios) butyric acid drug conjugates, sulfydryl polyethylene glycol and 4- (two sulphur of 2- pyridyl groups
Base) butyric acid drug conjugates molar ratio be 1:1~1:2, react at room temperature 12~36 it is small when, it is concentration, silica gel column purification, dense
Contracting, dissolving filter, are lyophilized, obtain the polyethylene glycol anticancer prodrugs containing disulfide bond.
The preparation method of the polymer prodrug of nano-micelle form of the present invention is as follows：
Polymer nano micelle is prepared using solvent volatile film aquation method.Specifically, polymer prodrug is added in
It is dissolved in ethyl alcohol, rotation is depressurized under 40-50 DEG C of water bath condition and is evaporated, water is added in after ethyl alcohol volatilizes in 50-60 DEG C of water-bath item
Aquation under part, the completely rear filter membrane of aquation, adds mannitol to freeze to get reduction response type polymer nano-micelle.
The amphipathic nature polyalcohol prodrug that release active compound is responded the present invention also provides reduction is preparing antitumor drug
In application.The tumour is colorectal cancer or breast cancer.By taking 7-Ethyl-10-hydroxycamptothecin as an example, reproducibility response
The mechanism for discharging active compound molecule is as follows：
The present invention reduction response release active compound the specific Mechanism of Drug Release of amphipathic nature polyalcohol prodrug be：In reducing agent
Under the action of, disulfide bond generates a free sulfydryl after being broken, and is influenced be subject to stable structure factor, the sulfydryl nucleophilic
The neighbouring ester bond of attack generates stable a five-membered ring or six-membered ring structure, while discharges active compound molecule.
Compared with prior art, the advantage of the invention is that：
1st, present invention employs the thinking of tumor microenvironment target administration, by introducing to the type self-destroyed of reducing environment sensitivity
Molecular rearrangement, while anticancer occur for disulfide bond linking arm, the disulfide bonds in the distinctive reducing environment of tumor tissues (GSH)
Drug quick release in the form of active compound molecule, so as to play the antitumous effect of specificity；Both nano medicament carrying system is remained
Advantage, while played disulfide bond the tumor locus selective degradation the characteristics of.With 3,3 ' conventional-dithiodipropionic acid etc.
Linking arm is compared, without can be obtained by the anticancer drug of active compound molecular forms by further hydrolyzing.
2nd, the amphipathic nature polyalcohol prodrug that the present invention obtains, can be spontaneously assemble into nano-micelle in a solvent.
3rd, the preparation method of the amphipathic nature polyalcohol prodrug of reduction response release active compound mentioned in the present invention has
The advantages that raw material is easy to get, reaction condition is mild, yield and product purity are high, beneficial to batch production.
Description of the drawings
Fig. 1 is the nuclear magnetic resonance spectroscopy of 4- mercaptobutyric acids prepared by embodiment 1；
Fig. 2 is the nuclear magnetic resonance spectroscopy (Fig. 2A) of 4- (2- pyridyidithios) butyric acid prepared by embodiment 1 and mass spectrum (figure
2B)；
Fig. 3 is the nuclear magnetic resonance spectroscopy of 4- (2- pyridyidithios) butyric acid and SN-38 conjugates prepared by embodiment 1
(Fig. 3 A) and mass spectrum (Fig. 3 B)；
Fig. 4 is the nuclear magnetic resonance spectroscopy of polyethylene glycol-disulfide bond-SN38 prodrugs prepared by embodiment 1；
Fig. 5 is the HPLC spectrograms of verification polyethylene glycol-disulfide bond-SN38 prodrugs reduction response release active compound；
Fig. 6 is the mechanism of polyethylene glycol-disulfide bond-SN38 prodrugs reduction response release SN-38 active compounds；
Fig. 7 is the grain size distribution of polyethylene glycol-disulfide bond-SN38 micellas prepared by embodiment 7；
Fig. 8 is the transmission electron microscope picture of polyethylene glycol-disulfide bond-SN38 micellas prepared by embodiment 7；
Fig. 9 is polyethylene glycol-disulfide bond-SN38 micellas prepared by embodiment 7 and SN-38 to colorectal cancer cell HCT116
The proliferation inhibition activity of (Fig. 9 A), HT29 (Fig. 9 B)；
Figure 10 is the multiplication of polyethylene glycol-disulfide bond-SN38 micellas prepared by embodiment 7 and SN-38 to breast cancer MCF-7
Inhibitory activity.
Specific embodiment
It further illustrates by the following examples and explains the present invention, but not as limitation of the present invention.
The synthesis of embodiment 1, polyethylene glycol-disulfide bond-SN38
(1) preparation of 4- mercaptobutyric acids：
4- bromo-butyric acids (10g, 59.9mmol) and thiocarbamide (6.37g, 83.8mmol) are added in 250mL ethyl alcohol, reflux 4 is small
When.After NaOH (24g, 600mmol) is dissolved in 250mL ethyl alcohol, add in reaction system in, continue reflux 16 it is small when.It is cooled to room
White solid is obtained by filtration in temperature, is dissolved in water.Water is mutually washed with ether, liquid separation, after being adjusted to pH 1 with 2M HCl, ether extraction, and nothing
Aqueous sodium persulfate is dried, and is dried in vacuo to obtain 4.9g pale yellow oils, yield 68%.Product after testing1H NMR, show
To the 4- mercaptobutyric acids of structure shown in formula a, such as Fig. 1.
(2) preparation of 4- (2- pyridyidithios) butyric acid：
4- mercaptobutyric acids (4.9g, 40.8mmol) and two sulphur, two pyridine (Py-SS-Py, 18g, 81.7mmol) are dissolved in
In 60mL methanol, when reaction 3 is small at room temperature.Decompression boils off methanol, crosses neutral alumina post separation, and concentration is dried in vacuo
5.4g pale yellow oils, yield 58%.Product after testing1H NMR show to obtain 4- (the 2- pyridyl groups of structure shown in formula b
Disulfide group) butyric acid, such as Fig. 2A and Fig. 2 B.
(3) preparation of 4- (2- pyridyidithios) butyric acid and SN-38 conjugates：
By SN-38 (2.0g, 5.1mmol), 4- (2- pyridyidithios) butyric acid (1.3g, 5.6mmol), 4- dimethylaminos
Pyridine (DMAP, 0.80g, 6.5mmol), n,N-diisopropylethylamine (DIEA, 1.1ml, 6.5mmol) are dissolved in 160mL DMF,
1- ethyls -3- (dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (EDCI, 1.25g, 6.5mmol), room temperature are added under ice bath
It is lower reaction 48 it is small when.Dichloromethane (DCM) is added in reaction solution, is washed successively with dilute hydrochloric acid, saturated sodium bicarbonate, saturated common salt
Organic phase, liquid separation, after dry, decompression boils off solvent.Through silica gel column purification, concentration is dried in vacuo to obtain 2.3g yellow solids, yield
For 75%.Product after testing1H NMR show to obtain 4- (2- pyridyidithios) butyric acid of structure shown in formula c and SN-38
Conjugate (Py-SS-SN38), such as Fig. 3 A and Fig. 3 B.
(4) preparation of polyethylene glycol-disulfide bond-SN38：
By mPEG2000- SH (4.9g, 2.4mmol) is dissolved in 100mL DMF, and under nitrogen protection, stirring, Py-SS- is added dropwise
DMF (100mL) solution of SN38 (1.8g, 2.9mmol), when reaction 24 is small at room temperature.Decompression boils off DMF, through silica gel column purification,
Concentration, after water dissolution, filtering, filtrate freezes, and obtains 3.2g faint yellow solids, yield 53%.Product after testing1H NMR,
Show to obtain polyethylene glycol-disulfide bond-SN38, such as Fig. 4 of structure shown in formula d.
Said synthesis route is as follows：
Molecule weight occurs for polyethylene glycol-disulfide bond-SN38 disulfide bonds under the conditions of tumor tissues glutathione reduction
Row, while drug is discharged with active compound molecular forms.Using high performance liquid chromatography, before demonstrating polyethylene glycol-disulfide bond-SN38
Medicine reduction response releases active compound molecule, as shown in Figure 5.
The synthesis of embodiment 2, different molecular weight polyethylene glycol-disulfide bond-SN38
Synthetic method is with embodiment 1, wherein with mPEG1000- SH or mPEG5000- SH substitutes mPEG2000- SH obtains difference
The polyethylene glycol of molecular weight-disulfide bond-SN38 conjugates.
The synthesis of embodiment 3, polyethylene glycol-disulfide bond-Cabazitaxel
(1) preparation of 5- (2- pyridyidithios) valeric acid：
5- bromo-butyric acids (2g, 11mmol) and thiocarbamide (1.18g, 15.5mmol) are added in 60mL ethyl alcohol, when reflux 4 is small.
After NaOH (4.4g, 110mmol) is dissolved in 60mL ethyl alcohol, add in reaction system in, continue reflux 16 it is small when.It is cooled to room temperature,
White solid is obtained by filtration, is dissolved in water.Water is mutually washed with ether, liquid separation, and after being adjusted to pH 1 with 2M HCl, ether extraction is anhydrous
Sodium sulphate is dried, and is dried in vacuo to obtain 0.88g pale yellow oils.
(2) pale yellow oil and two sulphur, two pyridine (Py-SS-Py, 2.9g, 13.1mmol) are dissolved in 30mL methanol,
When reaction 3 is small at room temperature.Decompression boils off methanol, crosses neutral alumina post separation, and concentration is dried in vacuo to obtain the faint yellow oil of 1.04g
Shape object.Two-step reaction yield is 39%.Product after testing1H NMR show to obtain 5- (the 2- pyridyl groups two of structure shown in formula e
Sulfenyl) valeric acid.
(3) preparation of 5- (2- pyridyidithios) valeric acids and Cabazitaxel conjugate：
By Cabazitaxel (1.0g, 1.2mmol), 5- (2- pyridyidithios) valeric acid (0.3g, 1.3mmol), 4- diformazans
Aminopyridine (DMAP, 0.18g, 1.5mmol), n,N-diisopropylethylamine (DIEA, 0.25ml, 1.5mmol) are dissolved in 50mL
In DMF, 1- ethyls -3- (dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate (EDCI, 0.3g, 1.5mmol) is added under ice bath,
When reaction 48 is small at room temperature.Dichloromethane (DCM) is added in reaction solution, successively with dilute hydrochloric acid, saturated sodium bicarbonate, saturated common salt
Organic phase is washed, liquid separation, after dry, decompression boils off solvent.Through silica gel column purification, concentration, be dried in vacuo 0.95g yellow is consolidated
Body, yield 75%.Product after testing1H NMR show to obtain 5- (2- pyridyidithios) valeric acid of structure shown in formula f
With Cabazitaxel conjugate (Py-SS- Cabazitaxels).
(4) preparation of polyethylene glycol-disulfide bond-Cabazitaxel：
By mPEG2000- SH (1.0g, 0.5mmol) is dissolved in 30mL DMF, and under nitrogen protection, stirring, Py-SS- cards are added dropwise
DMF (30mL) solution of Ba Tasai (0.64g, 0.6mmol), when reaction 24 is small at room temperature.Decompression boils off DMF, pure through silicagel column
Change, concentration, after water dissolution, filtering, filtrate freezes, and obtains 0.88g faint yellow solids, yield 60%.Product after testing1H
NMR shows to obtain polyethylene glycol-disulfide bond-Cabazitaxel of structure shown in formula g.
Said synthesis route is as follows：
The synthesis of embodiment 4, different molecular weight polyethylene glycol-disulfide bond-Cabazitaxel
Synthetic method is with embodiment 3, wherein with mPEG1000- SH or mPEG5000- SH substitutes mPEG2000- SH obtains difference
Polyethylene glycol-disulfide bond-Cabazitaxel conjugate of molecular weight.
The synthesis of embodiment 5, polyethylene glycol-disulfide bond-vinorelbine
(1) preparation of 4- (2- pyridyidithios) butyric acid and vinorelbine conjugate：
The preparation method of 4- (2- pyridyidithios) butyric acid is the same as embodiment 1.By vinorelbine (2.0g, 2.6mmol), 4-
(2- pyridyidithios) butyric acid (0.66g, 2.9mmol), 4-dimethylaminopyridine (DMAP, 0.40g, 3.3mmol), N, N- bis-
Wopropyl ethyl amine (DIEA, 0.55ml, 3.3mmol) is dissolved in 160mL DMF, and 1- ethyl -3- (dimethylaminos are added under ice bath
Propyl) phosphinylidyne diimmonium salt hydrochlorate (EDCI, 0.62g, 3.3mmol), when reaction 48 is small at room temperature.Dichloromethane is added in reaction solution
Alkane (DCM), successively with dilute hydrochloric acid, saturated sodium bicarbonate, saturated common salt washing organic phase, liquid separation, after dry, decompression boils off molten
Agent.Through silica gel column purification, concentration is dried in vacuo to obtain 1.5g yellow solids, yield 58%.Product after testing1H NMR, table
Bright 4- (2- pyridyidithios) butyric acid for obtaining structure shown in formula h and vinorelbine conjugate (Py-SS- vinorelbines).
(4) preparation of polyethylene glycol-disulfide bond-vinorelbine：
By mPEG2000- SH (2.0g, 1.0mmol) is dissolved in 50mL DMF, and under nitrogen protection, stirring, Py-SS- long is added dropwise
DMF (50mL) solution of spring Rui Bin (1.2g, 1.2mmol), when reaction 24 is small at room temperature.Decompression boils off DMF, pure through silicagel column
Change, concentration, after water dissolution, filtering, filtrate freezes, and obtains 1.2g white-yellowish solids, yield 42%.Product after testing1H
NMR shows to obtain polyethylene glycol-disulfide bond-vinorelbine of structure shown in formula i.
Said synthesis route is as follows：
The synthesis of embodiment 6, different molecular weight polyethylene glycol-disulfide bond-vinorelbine
Synthetic method is with embodiment 5, wherein with mPEG1000- SH or mPEG5000- SH substitutes mPEG2000- SH obtains difference
Polyethylene glycol-disulfide bond-vinorelbine conjugate of molecular weight.
The preparation of embodiment 7, polyethylene glycol-disulfide bond-SN38 micellas and characterization
Polymer nano micelle is prepared using solvent volatile film aquation method.Before polymeric medicine prepared by embodiment 1
Body, which is added in ethyl alcohol, to be dissolved, and rotation is depressurized under 40 DEG C of water bath conditions and is evaporated, and water is added in after ethyl alcohol volatilizes in 55 DEG C of water-bath items
Aquation under part, the completely rear filter membrane of aquation, adds mannitol to freeze to get reduction response type polymer nano-micelle.Utilize dynamic
Light scattering (Dynamic Light Scattering, DLS) measure obtains grain size and the distribution of nano-micelle, such as Fig. 7；And with thoroughly
The pattern of electron microscope (Transmission Electron Microscope, TEM) observation polymer nano micelle is penetrated, such as
Fig. 8.
The colorectal cancer cell proliferation inhibition test of embodiment 8, polyethylene glycol-disulfide bond-SN38 micellas
Polyethylene glycol prepared by embodiment 7-disulfide bond-SN38 micellas carry out extracorporeal anti-tumor cell effect with SN-38
Contrast test.By taking colorectal cancer HCT116, HT29 as an example, the cell in growth period of taking the logarithm adjusts appropriate cell density, inoculation
In in 96 orifice plates, 100 μ l/well are incubated at 37 DEG C, in the incubator of 5%CO2.It is administered after overnight incubation, respectively dosing effect
48h.Set up blank group, administration group separately, every group sets 4 multiple holes.Tuberculosis in vitro carcinoma of the rectum effect is as shown in fig. 9 a and fig. 9b.From Fig. 9 A
With in Fig. 9 B as can be seen, polyethylene glycol-disulfide bond-SN38 and SN-38 have approximate cytotoxicity ,-two sulphur of polyethylene glycol
Key-SN38 is 0.219 μM to the median lethal dose IC50 of colorectal cancer HCT116, to the median lethal dose of colorectal cancer HT29
IC50 is 1.67 μM, there is stronger antitumor activity.
The Cells Proliferation of Human Breast Cancer Inhibition test of embodiment 9, polyethylene glycol-disulfide bond-SN38 micellas
Polyethylene glycol prepared by embodiment 7-disulfide bond-SN38 micellas carry out extracorporeal anti-tumor cell effect with SN-38
Contrast test.By taking breast cancer MCF-7 as an example, the cell in growth period of taking the logarithm adjusts appropriate cell density, is inoculated in 96 orifice plates
Interior, 100 μ l/well are incubated at 37 DEG C, in the incubator of 5%CO2.It is administered after overnight incubation, respectively dosing effect 48h.Set up separately
Blank group, administration group, every group sets 4 multiple holes.External anti-breast cancer cell effect is as shown in Figure 10.As can be seen from Figure 10,
Polyethylene glycol-disulfide bond-SN38 and SN-38 has approximate cytotoxicity, and polyethylene glycol-disulfide bond-SN38 is to breast cancer
The median lethal dose IC50 of MCF-7 is 2.80 μM.
Claims (9)
- A kind of 1. amphipathic nature polyalcohol prodrug for reducing response release active compound, which is characterized in that the following institute of its general structure Show：Wherein, n is 5~400；M is 1 or 2；R is hydrophobic anticancer drug.
- 2. the amphipathic nature polyalcohol prodrug of reduction response release active compound according to claim 1, it is characterised in that：Institute The hydrophobic anticancer drug stated is camptothecin either taxanes or vinca.
- 3. the amphipathic nature polyalcohol prodrug of reduction response release active compound according to claim 2, it is characterised in that：Institute Stating camptothecin antineoplastic agents includes camptothecine, Irinotecan, topotecan, 10-hydroxycamptothecine, 7- ethyl -10- hydroxyls Camptothecine, taxane anti-tumor medicament include taxol, Docetaxel, Cabazitaxel, Antitumor Agents Vinblastine Analogues bag Include vincaleukoblastinum, vincristine, vinorelbine.
- 4. according to the preparation side of the amphipathic nature polyalcohol prodrug of any reduction response release active compounds of claim 1-3 Method includes the following steps：(1) 4- bromo-butyric acids are reacted with thiocarbamide, obtain 4- mercaptobutyric acids；4- (two sulphur of 2- pyridyl groups containing disulfide bond is obtained by the reaction in the 4- mercaptobutyric acids that two pyridine of (2) two sulphur is obtained with step (1) Base) butyric acid；(3) 4- (2- pyridyidithios) butyric acid containing disulfide bond that step (2) obtains is being catalyzed with hydrophobic anticancer drug Under agent effect, by being condensed to yield 4- (2- pyridyidithios) butyric acid drug conjugates；(4) step (3) obtains 4- (2- pyridyidithios) butyric acid drug conjugates and sulfydryl polyethylene glycol by sulfydryl- Disulfide bond exchange reaction obtains the amphiphilic of the polyethylene glycol anticancer prodrugs containing disulfide bond, i.e. reduction response release active compound Property polymer prodrug.
- 5. the preparation method of the amphipathic nature polyalcohol prodrug of reduction response release active compound according to claim 4, It is characterized in that：Step (1) includes following reaction step：By 4- bromo-butyric acids and thiocarbamide in molar ratio 1:1~1:3 add in ethyl alcohol, reflux 2 ~8 it is small when, then add in NaOH ethanol solutions continue reflux 6~20 it is small when, cooling, filtering, dissolving, ether wash, liquid separation, tune PH, extraction, dry 4- mercaptobutyric acids；Step (2) includes following reaction step：By 4- mercaptobutyric acids and two sulphur, two pyridine in molar ratio 1:1~1:5 are dissolved in methanol In, react at room temperature 1~5 it is small when, concentration, neutral alumina column and silica gel post separation, concentration, dry 4- (2- pyridyl groups two Sulfenyl) butyric acid；Step (3) includes following reaction step：In the presence of condensing agent and organic amine, by hydrophobic anticancer drug and 4- (2- Pyridyidithio) butyric acid in molar ratio 1:1~1:3 are dissolved in DMF, room temperature reaction 36~72 it is small when, reaction solution through pickling, in With liquid separation, drying, silica gel column purification, concentration, be dried in vacuo to obtain 4- (2- pyridyidithios) butyric acid drug conjugates；Step (4) includes following reaction step：Under nitrogen protection, sulfydryl polyethylene glycol is added dropwise to 4- under stirring condition In the DMF solution of (2- pyridyidithios) butyric acid drug conjugates, sulfydryl polyethylene glycol and 4- (2- pyridyidithios) The molar ratio of butyric acid drug conjugates is 1:1~1:2, react at room temperature 12~36 it is small when, it is concentration, silica gel column purification, concentration, molten Solution, filtering freeze, and obtain the polyethylene glycol anticancer prodrugs containing disulfide bond.
- 6. a kind of nano-micelle preparations for the amphipathic nature polyalcohol prodrug for reducing response release active compound, which is characterized in that by The amphipathic nature polyalcohol prodrug of any reduction response release active compounds of claim 1-3 is made, the nano-micelle Grain size in 10~400nm, drugloading rate is 1%~50%.
- 7. the preparation method of nano-micelle preparations described in claim 6, which is characterized in that using solvent volatile film aquation legal system Standby nano-micelle, polymer prodrug is added in ethyl alcohol and is dissolved, and rotation is depressurized under 40-50 DEG C of water bath condition and is evaporated, is treated Ethyl alcohol adds in water aquation under 50-60 DEG C of water bath condition after volatilizing, the completely rear filter membrane of aquation adds mannitol to freeze to get also Former response type polymer nano-micelle.
- 8. the amphipathic nature polyalcohol prodrug of the reduction response release active compound as described in claim 1-3 is any is anti-swollen in preparation Application in tumor medicine.
- 9. the amphipathic nature polyalcohol prodrug of reduction response release active compound as claimed in claim 8 is preparing antitumor drug In application, which is characterized in that the tumour be colorectal cancer or breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611007592.5A CN108066770B (en) | 2016-11-16 | 2016-11-16 | Amphiphilic polymer prodrug capable of releasing original drug in reduction response manner and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611007592.5A CN108066770B (en) | 2016-11-16 | 2016-11-16 | Amphiphilic polymer prodrug capable of releasing original drug in reduction response manner and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108066770A true CN108066770A (en) | 2018-05-25 |
| CN108066770B CN108066770B (en) | 2022-10-14 |
Family
ID=62163246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611007592.5A Active CN108066770B (en) | 2016-11-16 | 2016-11-16 | Amphiphilic polymer prodrug capable of releasing original drug in reduction response manner and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066770B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108676156A (en) * | 2018-06-25 | 2018-10-19 | 河南师范大学 | A kind of reduction response type ABC type block polymers and its preparation method and application |
| CN110840850A (en) * | 2018-07-24 | 2020-02-28 | 烟台药物研究所 | Celecoxib freeze-dried orally disintegrating tablet with high bioavailability and preparation method thereof |
| CN111110860A (en) * | 2018-10-31 | 2020-05-08 | 烟台药物研究所 | Reduction response type Her2 targeted polypeptide drug conjugate and preparation method and application thereof |
| CN111110858A (en) * | 2018-10-31 | 2020-05-08 | 烟台药物研究所 | Her2 targeted polypeptide drug conjugate as well as preparation method and application thereof |
| CN112321615A (en) * | 2020-10-30 | 2021-02-05 | 华中科技大学 | Camptothecin-based dimer compound, and preparation and application thereof |
| CN113041355A (en) * | 2021-04-21 | 2021-06-29 | 浙江大学 | Co-delivery nano-drug capable of accurately regulating and controlling ratio of combined drug and application |
| WO2022088679A1 (en) * | 2020-10-30 | 2022-05-05 | 华中科技大学 | Method for removing tumor stem cells, anti-cancer drug, drug delivery system, and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705943A (en) * | 2014-01-03 | 2014-04-09 | 北京大学 | Preparation method and application of reduction-response-type pegylation (PEG) nanomedicine composition |
-
2016
- 2016-11-16 CN CN201611007592.5A patent/CN108066770B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103705943A (en) * | 2014-01-03 | 2014-04-09 | 北京大学 | Preparation method and application of reduction-response-type pegylation (PEG) nanomedicine composition |
Non-Patent Citations (1)
| Title |
|---|
| XUN LIU ET AL.: ""A multi-stimuli responsive nanoparticulate SN38 prodrug for cancer chemotherapy"", 《JOURNAL OF MATERIALS CHEMISTRY B》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108676156A (en) * | 2018-06-25 | 2018-10-19 | 河南师范大学 | A kind of reduction response type ABC type block polymers and its preparation method and application |
| CN108676156B (en) * | 2018-06-25 | 2021-02-02 | 河南师范大学 | Reduction response type ABC type block polymer and preparation method and application thereof |
| CN110840850A (en) * | 2018-07-24 | 2020-02-28 | 烟台药物研究所 | Celecoxib freeze-dried orally disintegrating tablet with high bioavailability and preparation method thereof |
| CN111110860A (en) * | 2018-10-31 | 2020-05-08 | 烟台药物研究所 | Reduction response type Her2 targeted polypeptide drug conjugate and preparation method and application thereof |
| CN111110858A (en) * | 2018-10-31 | 2020-05-08 | 烟台药物研究所 | Her2 targeted polypeptide drug conjugate as well as preparation method and application thereof |
| CN112321615A (en) * | 2020-10-30 | 2021-02-05 | 华中科技大学 | Camptothecin-based dimer compound, and preparation and application thereof |
| CN112321615B (en) * | 2020-10-30 | 2021-11-09 | 华中科技大学 | Camptothecin-based dimer compound, and preparation and application thereof |
| WO2022088679A1 (en) * | 2020-10-30 | 2022-05-05 | 华中科技大学 | Method for removing tumor stem cells, anti-cancer drug, drug delivery system, and use thereof |
| CN113041355A (en) * | 2021-04-21 | 2021-06-29 | 浙江大学 | Co-delivery nano-drug capable of accurately regulating and controlling ratio of combined drug and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108066770B (en) | 2022-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108066770A (en) | Amphipathic nature polyalcohol prodrug of reduction response release active compound and preparation method thereof | |
| CN102060991B (en) | Amphiphilic prodrug of 7- ethyl-10-hydroxycamptothecin and preparation method thereof | |
| CN103804472B (en) | A kind of taxone precursor | |
| JP6867084B2 (en) | New cationic polyphosphazene compounds, polyphosphazene-drug conjugate compounds and methods for producing them | |
| CN105617394A (en) | Self-assembled nano-system of unsaturated fatty acid-anti-tumor drug conjugates as well as preparation method and application thereof | |
| CN112047952B (en) | Camptothecin-photosensitizer prodrug and preparation method and application thereof | |
| CN104971353B (en) | The preparation and application of the amphiphilic polysaccharide derivative carrier and its pharmaceutical compositions of target tumor new vessels | |
| CN103705943A (en) | Preparation method and application of reduction-response-type pegylation (PEG) nanomedicine composition | |
| CN109303780B (en) | Reduction response type amphiphilic polymer prodrug of 7-ethyl-10-hydroxycamptothecin and preparation method thereof | |
| CN106916236B (en) | A kind of cyclodextrin-camptothecin supermolecule chemotherapeutics and its preparation and application | |
| CN107417752A (en) | One kind has compound of active anticancer and its preparation method and application | |
| CN104548124A (en) | Water-soluble biodegradable anti-tumor prodrug and preparation method of anti-tumor prodrug | |
| CN108836937B (en) | Cisplatin nano-medicine preparation, preparation method and application | |
| CN109675053A (en) | Targeting preparation of Podophyllotoxin and its derivatives and preparation method thereof | |
| KR101942159B1 (en) | Anti-cancer drug and diosgenin conjugates, preparation method thereof, and anti-cancer composition comprising the same | |
| CN105504293A (en) | Preparation and application of fluorescent star-shaped block copolymer | |
| CN102336904B (en) | Multivalent polyglycol (PEG) modifier for camptothecin and derivatives thereof and application of multivalent PEG modifier | |
| CN106620714A (en) | 7-ethyl-10-hydroxycamptothecine-polymer conjugated drug and preparation method of drug nano-preparation | |
| CN107090082A (en) | A kind of Salanesol derivative, its preparation method and application with tumor tissues reduction-sensitive | |
| CN101029034B (en) | Polyenic taxol soluble derivative, its preparation and use | |
| Zhang et al. | Preparation, characterization and in vivo antitumor evaluation of a micellar formulation of camptothecin prodrug | |
| Gao et al. | Hydrotropic polymer-based paclitaxel-loaded self-assembled nanoparticles: preparation and biological evaluation | |
| CN103055321A (en) | Methoxy polyethylene glycol-polyphosphate diblock copolymer and adriamycin bonding medicine thereof | |
| CN110025574A (en) | A kind of reduction response type amphipathic stem polymer prodrug and its preparation method and application | |
| CN110314238A (en) | A kind of polypeptide drugs conjugate of cancer target and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |